Skip to content

ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

 
  • En
  • Sv
  • About us
    • Management
    • Board of Directors
  • Therapeutic areas
    • Liver metastases
    • Gastric Cancer
  • Pipeline
    • Orviglance®
    • Oncoral
  • Partnering
  • Investors
    • Press releases
    • Financial reports
    • Presentations & articles
    • Events
    • Share information
    • Shareholders
    • Insiders
    • Equity research
    • Financial calendar
  • Governance
    • General Meeting
    • Articles of Association
    • Nomination Committee
    • Board of Directors
    • Audit Committee
    • Remuneration Committee
    • Commercialization Committee
    • Remuneration
    • Auditors
    • Internal control
  • Career
    • Open positions
    • Our values
  • Contact
18 events found.

Events

Events Search and Views Navigation

Event Views Navigation

  • List
Today
  • May 2024

  • Tue 21

    HC Andersen – Presentation of Q1 2024

    2024-05-21 @ 13:00 - 13:20

    Magnus Corfitzen will present the Q1 interim report. To register to the event: Ascelia Pharma - What happened during Q1 2024  

  • Mon 27

    Carnegie Heathcare

    2024-05-27 @ 08:00 - 2024-05-30 @ 17:00

    Ascelia Pharma will present at the Carnegie Healthcare Conference.

  • June 2024

  • Tue 4

    HC Andersen – Life Science Seminar

    2024-06-04 @ 10:00 - 10:30

    Ascelia Pharma will present at the HC Andersen Life Science Seminar, to attend: https://www.inderes.dk/videos/life-science-seminar-2024

  • Mon 17

    Commercial and partnership strategy

    2024-06-17 @ 10:30 - 11:00

    Julie Waras Brogren, Deputy CEO will present the commercial and partnership strategy for Orviglance, to register and submit your questions: Ascelia Pharma commercial and partnership strategy

  • August 2024

  • Thu 15

    Half-year report 2024

    2024-08-15
  • Mon 19

    Update Q2 2024 and rights issue

    2024-08-19 @ 14:30 - 15:00

    Julie Waras Brogren will present the Q2 interim report at a virtual live event for investors. To register:  Update Q2 2024

  • Thu 29

    Small-Cap Day with Carnegie

    2024-08-29 @ 13:35 - 14:00
    Carnegie office at Regeringsgatan 56 in Stockholm

    Magnus Corfitzen will present at Cargenie. The presentation will be live streamed: Ascelia Pharma Live Presentation  

  • September 2024

  • Tue 10

    Ascelia Pharma – Final outcome of rights issue with HC Andersen

    2024-09-10 @ 14:00 - 14:30

    Magnus Corfitzen will present the final outcome of the Rights issue. You can already sign up for the event: Ascelia Pharma Final Outcome Of Rights Issue  

  • November 2024

  • Thu 7

    Interim Report 9M 2024

    2024-11-07
  • Mon 11

    Presentation of Q3 2024 results

    2024-11-11 @ 14:00 - 14:30

    Julie Waras Brogren, Deputy CEO will present Q3 2024 results. To register to the event: Ascelia Pharma - What Happened During Q3 2024

  • Tue 19

    Jefferies Healthcare Conference

    2024-11-19 @ 08:00 - 2024-11-21 @ 17:00
    London

    Ascelia Pharma will be at the Jefferies Healthcare conference.

  • December 2024

  • Sun 1

    Ascelia Pharma will present at the world’s largest radiology conference

    2024-12-01 @ 08:00 - 2024-12-05 @ 17:00
    Chicago

    Ascelia Pharma will present Orviglance SPARKLE study primary results as oral presentation in cutting edge research at the 2024 RSNA annual meeting. Timing of presentation: 2 Dec, 13:30-14:00 CDT, local time Chicago  

  • January 2025

  • Thu 16

    Seminar for institutional investors with HC Andersen

    2025-01-16 @ 08:00 - 17:00
    Copenhagen

    Ascelia Pharma will present at the institutional investor seminar, to register: investor seminar registration

  • Wed 22

    Redeye Fight Cancer Event

    2025-01-22 @ 12:55 - 13:30

    Ascelia Pharma will present at the Redeye Fight Cancer Event. You can send in your question: Ask your questions

  • February 2025

  • Fri 7

    Full-year report 2024

    2025-02-07
  • Fri 7

    Presentation of Full year and Q4 2024 – HC Andersen

    2025-02-07 @ 13:30 - 14:00

    Julie Waras Brogren will present the full year and Q4 2024. To register: Ascelia Pharma – Presentation of Full year and Q4 report

  • March 2025

  • Thu 13

    Carnegie Healthcare day

    2025-03-13 @ 10:50 - 11:10
    Stockholm

    Magnus Corfitzen will present at Carnegie Healthcare day.

  • Wed 26

    Investor Conference with ØU Life Science

    2025-03-26 @ 14:05 - 14:40
    Symbion, Fruebjergvej 3, 2100 Copenhagen

    Magnus Corfitzen will present at the ØU Life Science conference. To  register: Investor event - 26 March   

  • Previous Events
  • Today
  • Next Events
  • Google Calendar
  • iCalendar
  • Outlook 365
  • Outlook Live
  • Export .ics file
  • Export Outlook .ics file
Learn more

About us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance®  and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and i ...
Learn more

Contact

Magnus Corfitzen will present at the ØU Life Science conference. To  register: Investor event - 26 March    ...
Learn more

Our values

Our values inspire our ambitions, decision making and collaboration to help us reach our highest potential. INTEGRITY We build powerful relationship with mutual respect and adhere to the high ethical standards of our industry COURAGE We work tirelessly and follow our convictions even when it means changing status quo  FOCUS We are devoted to i ...
  1. Start (en)
  2. Calendar
  3. List

About us

  • Start (en)
  • About us
  • Career
  • Contact
  • Privacy policy
  • About cookies
  • Cookie settings
  • IMPORTANT INFORMATION

Pipeline

  • Oncoral
  • Orviglance®

IR & Media

  • Subscribe to press releases
  • Press releases & News
  • Financial Reports

Contact us

Ascelia Pharma AB
Hyllie Boulevard 34
215 32 Malmö
Sweden
Phone: +46 735 17 91 18

info@ascelia.com

Follow us

 

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development.

Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

© Copyright 2021 - Ascelia Pharma AB | We use cookies to improve our services | Disclaimer Market data could be delayed. Delivered by Modular Finance.

Video
Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all